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OBJECTIVE—This study aimed to estimate the current cumu-
lative risk of end-stage renal disease (ESRD) due to diabetic
nephropathy in a large, nationwide, population-based prospec-
tive type 1 diabetes cohort and speciﬁcally study the effects of
sex and age at onset.
RESEARCH DESIGN AND METHODS—In Sweden, all inci-
dent cases of type 1 diabetes aged 0–14 years and 15–34 years are
recorded in validated research registers since 1977 and 1983,
respectively. These registers were linked to the Swedish Renal
Registry, which, since 1991, collects data on patients who receive
active uremia treatment. Patients with 13 years duration of type
1 diabetes were included (n  11,681).
RESULTS—During a median time of follow-up of 20 years, 127
patients had developed ESRD due to diabetic nephropathy. The
cumulative incidence at 30 years of type 1 diabetes duration was
low, with a male predominance (4.1% [95% CI 3.1–5.3] vs. 2.5%
[1.7–3.5]). In both male and female subjects, onset of type 1
diabetes before 10 years of age was associated with the lowest
risk of developing ESRD. The highest risk of ESRD was found in
male subjects diagnosed at age 20–34 years (hazard ratio 3.0 [95%
CI 1.5–5.7]). In female subjects with onset at age 20–34 years, the
risk was similar to patients’ diagnosed before age 10 years.
CONCLUSIONS—The cumulative incidence of ESRD is excep-
tionally low in young type 1 diabetic patients in Sweden. There is
a striking difference in risk for male compared with female
patients. The different patterns of risk by age at onset and sex
suggest a role for puberty and sex hormones. Diabetes 59:
1803–1808, 2010
D
iabetic nephropathy is one of the most severe
complications in patients with type 1 diabetes,
leading to end-stage renal disease (ESRD) and
the need for renal replacement therapy (dialysis
and transplantation). Diabetic nephropathy is also a major
predictor of cardiovascular morbidity and mortality in
patients with type 1 diabetes (1). Although the incidence
of type 1 diabetes has increased in children, and onset of
disease occurs at younger age (2,3), a decrease in inci-
dence of diabetic nephropathy and a longer duration from
onset of diabetes to diabetic nephropathy and ESRD has
been reported from dedicated centers (4). Recently, a
follow-up of the Diabetes Control and Complications
Trial–intensive treated type 1 diabetes case subjects
showed a cumulative incidence of nephropathy of 9% at 30
years of diabetes duration compared with 25% in the
conventionally treated group (5). A Finnish population-
based study showed a cumulative incidence of ESRD of
7.8% after 30 years of diabetes duration (6). Next to
Finland, Sweden has the highest incidence of childhood-
onset diabetes reported worldwide (7), and since the
1980s Sweden has a strict nationwide childhood diabetes
care program that includes intensive insulin treatment and
home blood glucose monitoring to counteract develop-
ment of late complications.
Poor glycemic control and high blood pressure are the
two most important risk factors in the initiation and
development of diabetic nephropathy (8,9), but they are
not sufﬁcient for development of diabetic nephropathy and
ESRD. Other factors, such as genetic susceptibility and
growth and sex hormones, seem to contribute (10,11).
Some studies (12–14) suggest that male sex is a risk factor
for development of diabetic nephropathy and ESRD. Sev-
eral studies (6,15,16) indicate that young age at onset of
diabetes can prolong the time until development of mi-
croalbuminuria, diabetic nephropathy, ESRD, and other
vascular complications. It has thus been suggested that
puberty could promote the development of chronic diabe-
tes complications due to deterioration of glycemic control,
rapid growth, and hormonal changes (17,18). An increased
risk for both hospitalization due to severe vascular com-
plications and a higher mortality rate have also been found
in patients with pubertal onset of diabetes compared with
those with younger age at onset (19,20). If puberty is
associated with increased risk of diabetic nephropathy,
diabetes onset after that age would decrease diabetic
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onset cases.
In the present study, we used data from two large,
nationwide, population-based cohorts of young patients
with type 1 diabetes for the following reasons:
● to estimate the cumulative incidence and long-term risk
of ESRD after 30 years of type 1 diabetes with recom-
mended intensive insulin treatment; and
● to study the effects of age at onset of diabetes and sex on
these risks.
RESEARCH DESIGN AND METHODS
Since 1 July 1977, all incident cases of type 1 diabetes in those aged 0–14 years
are recorded in the Swedish Childhood Diabetes Registry (SCDR). Only those
who are insulin treated from diagnosis (99% of cases) are registered.
Comparisons with external sources have shown that the level of ascertain-
ment in the SCDR is 96–99% (21,22). The Diabetes Incidence Study in Sweden
(DISS) records incident cases of diabetes in the age-group 15–34 years since
1 January 1983. The completeness of the DISS register has varied between 82
and 91%, depending on the source of ascertainment (23), with no signiﬁcant
sex difference. The classiﬁcation into type 1, type 2, and unclassiﬁed diabetes
is based on the treating doctors’ clinical classiﬁcation. During 1983–1991, the
World Health Organization classiﬁcation was used, and since 1992 the
American Diabetes Association classiﬁcation criteria were used. This change
in diagnostic criteria would probably little affect the results, since only
clinically overt cases of type 1 diabetes were included. Of all patients, 10%
who were classiﬁed by clinical criteria as having type 1 diabetes at diagnosis
are misclassiﬁed when the diagnosis was checked using autoantibodies and
C-peptide (24).
ESRD is deﬁned as need to start active uremia treatment due to renal
failure (glomerular ﬁltration rate 10–15 ml/min). The Swedish Renal Regis-
try (SRR) collects data on all patients with chronic renal failure who start
dialysis treatment or receive a kidney transplant. A validation study showed
that 95% of the patients who started treatment for chronic renal failure had
been reported to the SRR (25). The SRR started in 1991, and at that time none
of the patients in the SCDR had diabetes duration longer than 13 years.
When type of diabetes differed between the two diabetes registries and the
SRR, the classiﬁcation reported to the SRR was used since this was made after
a long clinical follow-up. Five patients were classiﬁed as having ESRD due to
type 2 diabetes in the SRR and were therefore excluded from the analyses.
Patients with ESRD due to other diagnoses than diabetes (n  11) were also
excluded.
The present study covers the majority of all cases of ESRD due to type 1
diabetes at 13 years duration or longer, during 1991–2007, and should hereby
represent the Swedish type 1 diabetic population at large. Patients with 13
years duration (i.e., diabetes onset 1 July 1977 to 31 December 1995 for the
SCDR and 1 January 1983 to 31 December 1995 for the DISS) would have equal
chance of entering the SRR, starting in 1991. Thus, 6,789 patients with onset
before age 15 years and 4,892 patients with onset of diabetes between age 15
and 34 years were included. Dates of death were obtained by linking the
diabetes registers to the Swedish Cause of Death Register.
This study was approved by the regional research ethics committee in
Umeå, according to the Swedish law on research ethics and in line with the
principles of the Helsinki Declaration and the European convention on human
rights and biomedicine. The study and the statistical analysis were designed
and interpreted by the authors. The funding bodies had no role in the design
and conduct of the study; in collection, management, analysis, or interpreta-
tion of the data; or in preparation and approval of the manuscript.
Statistical analyses. The age at onset was divided into three groups, aged
0–9, 10–19, and 20–34 years; hence, the 10–19 age at onset group includes the
pubertal years for the vast majority of the cohort. Incidence rates of ESRD
were calculated as number of cases divided by number of years at risk in
6-year intervals (13–18, 19–24, and 25–30 years of diabetes). Kaplan-Meier
analyses were used to calculate the cumulative incidences. Cox regression
analyses were performed to estimate the hazard ratio (HR) of developing
ESRD, to compare the HR by age-at-onset groups and sex, and to adjust for the
potential confounding variables age at follow-up and sex. In these analyses,
the time at risk was calculated from onset of diabetes until ESRD (i.e., date of
ﬁrst treatment with renal replacement therapy), death, or 31 December 2007.
Kaplan-Meier analyses may overestimate the cumulative incidence when
the event of death is censored in the same way as when censoring for other
reasons. Therefore, we also computed the cumulative incidence when taking
into account death as a competing risk event. This method accounts for death
as an event that removes the risk of ESRD and hence provides a more
accurate estimate of the risk (26). SPSS 16.0 for Windows was used for the
Kaplan-Meier and Cox regression analyses, while the R statistical software
version 2.5.1 (The R foundation for statistical computing available at http://
www.r-project.org/index.html), with the function “cuminc” from the “cmprsk”
package, was used for calculations with death as a competing risk event.
RESULTS
Long-term incidence rate and cumulative incidence
of ESRD. The study included patients with at least 13
years duration of type 1 diabetes. In total, 127 patients had
developed ESRD due to type 1 diabetes, 79 in the SCDR
and 48 in the DISS (Table 1). No patient had developed
ESRD before 13 years duration of diabetes. Maximum
follow-up was 30.0 years for the SCDR and 24.9 years for
the DISS. The median follow-up time was 21.2 years for
patients in the SCDR and 18.9 for patients in the DISS. The
median time from onset of diabetes to ESRD was 21.7
(range 14.7–28.2) and 18.5 (13.7–24.8), respectively. The
overall incidence rate of ESRD during 237,592 person-
years of follow-up was 0.53 per 1,000 person-years.
Effect of age at onset and sex on development of
ESRD. Table 2 shows incidence rates of ESRD per 1,000
person-years of diabetes duration, at 13–18, 19–24, and
25–30 years after diabetes onset. The incidence increased
with increasing diabetes duration. The sharpest increase
in incidence was seen between 13–18 and 19–24 years,
while the increase between 19–24 and 25–30 years was
modest, partly due to the fact that the 20- to 34-year-onset
group could not contribute as they had a maximum
duration of 25 years.
Tables 3 and 4 show the cumulative incidences in the
different age-at-onset groups, by sex, with and without
TABLE 1
Number of patients with and without ESRD
Age at
diagnosis
(years)
Male subjects Female subjects
n (%)
Median (range)
time from
diabetes onset
to ESRD
(years)
n deaths (%) n (%)
Median (range)
time from
diabetes onset
to ESRD
(years)
n deaths (%)
Without
ESRD
With
ESRD
Without
ESRD
With
ESRD
Without
ESRD
With
ESRD
Without
ESRD
With
ESRD
0–9 1,984 (99.2) 15 (0.8) 23.1 (18.2–26.2) 23 (1.2) 4 (0.2) 1,860 (99.4) 11 (0.6) 21.7 (16.2–27.8) 10 (0.5) 4 (0.2)
10–19 2,244 (98.2) 41 (1.8) 20.8 (15.3–28.2) 30 (1.3) 9 (0.4) 1,796 (98.5) 28 (1.5) 18.9 (14.7–26.0) 15 (0.8) 5 (0.3)
20–34 2,267 (98.9) 25 (1.1) 18.6 (13.7–24.8) 86 (3.7) 10 (0.4) 1,403 (99.5) 7 (0.5) 17.9 (14.0–23.1) 27 (1.9) 1 (0.1)
0–34 6,495 (98.8) 81 (1.2) 20.7 (13.7–28.2) 139 (2.1) 23 (0.3) 5,059 (99.1) 46 (0.9) 19.5 (14.0–27.8) 52 (1.0) 10 (0.2)
Median (range) time from diabetes onset to ESRD and number of deaths with and without ESRD, by age at diagnosis and sex, in patients
with type 1 diabetes with at least 13 years duration.
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Only 224 of 11,681 patients (1.9%) had died, 33 of them
after having developed ESRD (Table 1). Therefore, the
analyses with death as competing risk did not change the
results. The overall mortality in the study was 0.94 deaths
per 1,000 person-years of diabetes duration. There was a
14 times higher risk of death among patients with ESRD
(HR 14 [95% CI 9.7–21]), adjusted for sex and age at
follow-up. Male patients had almost twice the risk of death
due to any cause, compared with female patients (1.9
[1.4–2.6]), adjusted for ESRD and age at follow-up.
Among patients who developed type 1 diabetes before
the age of 20 years, there was no difference between male
and female subjects as can be seen in the cumulative
incidence curves (Fig. 1). Male subjects who were aged
20–34 years when diagnosed with type 1 diabetes had
twice as high risk of ESRD as female subjects (HR 2.3 [95%
CI 0.99–5.3]). Taking death into account as competing risk
reduced the male/female risk increase marginally (2.2
[0.97–5.2]).
The cumulative incidences of ESRD for male and female
subjects in the different age-at-onset groups (0–9, 10–19,
and 20–34 years) are shown in Fig. 2. The lowest risk for
ESRD was found in male and female subjects with onset of
type 1 diabetes before 10 years of age (Fig. 2). Among male
patients, the risk of developing ESRD was signiﬁcantly
increased in those developing diabetes at 20–34 years of
age (HR 3.0 [95% CI 1.5–5.7]) as well as 10–19 years of age
(2.6 [1.5–4.7]), compared with the youngest age-at-onset
group (0–9 years). Taking death into account as a com-
peting risk did not change the results.
In female subjects, there was no difference in the risk of
developing ESRD with diagnosis of type 1 diabetes at age
20–34 years compared with diagnosis at younger than 10
years of age, (HR 1.4 [95% CI 0.5–3.6]). The highest risk
was observed for the 10–19 years age-group (2.8 [1.4–5.5])
(Fig. 2). Taking death into account as a competing risk did
not change the results. Using a grouping of age at onset
0–9, 10–14, 15–24, and 25–34 years did not change the
overall pattern of difference seen by sex.
DISCUSSION
In this nationwide population-based study of patients with
type 1 diabetes and at least 13 years duration, the cumu-
lative incidence of ESRD due to diabetic nephropathy is
surprisingly low (3.3% at 30 years of duration). The Swed-
ish Pediatric Association Working Group for Diabetes in
Children in the nationwide Diabetes in Childhood Care
Program already in 1982 (updated regularly) recom-
mended intensive insulin treatment and home blood
glucose monitoring. In adults, national guidelines for
treatment of diabetes were issued by the Swedish Board of
Health and Welfare in 1977 and since then regularly
updated. These guidelines also involve intensive treatment
of glucose and blood pressure, including ACE inhibition,
for type 1 diabetic patients. These active treatment pro-
grams may clearly contribute to the low rate of ESRD in
Sweden, and our ﬁndings are in accord with that of a
decrease in incidence of albuminuria as reported from a
dedicated center in Sweden (4).
Since the study is based on incidence registers, we have
no access to individual A1C data, but according to the
Swedish National Diabetes Register (NDR) since 1996
estimate markers of quality of care, the yearly mean A1C
values, have decreased from 8.5% (Diabetes Control and
Complications Trial standard) to 8.1% during the time
period 1996–2005.
Previous studies, from different populations with differ-
ent years of onset of diabetes, have reported a cumulative
incidence of ESRD of 7–13% at 20 years of diabetes
duration (27–29). The cumulative incidence seen in this
study is also lower than reported in a recent Finnish
nationwide population-based study, in which 2.2% at 20
years of follow-up and 7.8% at 30 years of follow-up were
found (6). The Finnish study also showed a time-period
effect, with a decline in cumulative incidence over time
(1965–1999). In our cohort, however, there was no differ-
ence in risk of ESRD depending on year of diabetes onset,
which may be explained by the later starting date of our
study (1977) and more active treatment programs for both
TABLE 2
Incidence rates per 1,000 person-years at 6-year intervals of diabetes duration (13–18, 19–24, and 25–30 years after diagnosis)
Age at diagnosis
(years)
Intervals of diabetes duration (years)
13–18 years (male/female) 19–24 years (male/female) 25–30 years (male/female)
0–9 0.1 (0.1 to 0.3)/0.2 (0.1 to 0.5) 1.9 (0.7–3.0)/1.0 (0.1–1.9) 2.8 (0.1–5.6)/3.0 (0.1–5.9)
10–19 1.0 (0.4–1.6)/1.7 (0.8–2.6) 4.3 (2.6–6.0)/2.2 (0.8–3.6) 4.6 (0.9–8.3)/2.8 (0.4 to 6.0)
20–34 1.3 (0.6–2.0)/0.8 (0.1–1.5) 3.6 (1.6–5.6)/0.9 (0.4 to 2.2) —
0–34 0.8 (0.5–1.1)/0.9 (0.5–1.3) 3.2 (2.3–4.2)/1.5 (0.8–2.2) 3.7 (1.4–5.9)/2.9 (0.8–5.1)
Data are incidence rate (95% CI).
TABLE 3
Cumulative incidences of ESRD with death as competing risk, by age at onset and sex, at different diabetes durations
Age at diagnosis
(years)
Duration of type 1 diabetes (years)
20 years (male/female) 25 years (male/female) 30 years (male/female)
0–9 0.1 (0.0–0.4)/0.2 (0.1–0.7) 1.3 (0.7–2.3)/0.7 (0.3–1.4) 2.3 (1.3–3.7)/1.9 (0.9–3.5)
10–19 1.0 (0.6–1.6)/1.3 (0.8–2.0) 3.3 (2.3–4.6)/2.4 (1.5–3.5) 5.2 (3.5–7.4)/3.2 (2.0–4.8)
20–34 1.0 (0.6–1.7)/0.7 (0.3–1.5) 5.7 (1.5–14.2)/1.1 (0.4–2.4) —
0–34 0.7 (0.5–1.0)/0.7 (0.5–1.0) 2.6 (2.0–3.3)/1.4 (1.0–2.0) 4.0 (3.0–5.2)/2.4 (1.6–3.5)
Data are incidence rate (95% CI). The cumulative incidence with death as a competing risk takes into account that death is an event
competing with the risk to develop ESRD.
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difference between the cohorts may also contribute to the
discrepancies in cumulative incidences. A decline in cu-
mulative incidence of ESRD has been indicated by an
unchanged reporting rate for type 1 diabetes in both the
European Dialysis and Transplant Association registry,
including the SRR, through the 1990–2000s, despite an
increase in prevalence of type 1 diabetes and longer
survival in patients with type 1 diabetes (30).
The peak incidence of diabetic nephropathy has been
found to occur 15–25 years after the onset of type 1
diabetes (27,31), and the median duration from onset of
diabetic nephropathy to ESRD is usually 10 years (27).
The development of ESRD due to diabetic nephropathy
within 15 years of diabetes duration is rare; in this study,
only three patients had developed ESRD before this dura-
tion. The relatively constant incidence rates at 19–24 and
25–30 years of diabetes duration may indicate that the
peak incidence of ESRD had been reached at 30 years of
diabetes duration or that the peak incidence has been
delayed beyond 30 years of diabetes duration. Both alter-
natives suggest a favorable change in the natural history of
diabetic nephropathy also in susceptible patients. These
ﬁndings of a favorable time trend in diabetes nephropathy
is in correspondence with the results of Pittsburg Epide-
miology of Diabetes Complications Study (32).
Our study conﬁrms previous ﬁndings of a reduced risk,
or a delay, in development of ESRD in patients diagnosed
with type 1 diabetes before the age 5 (n  2) and 10 years
(6,14,15,33). A similar age dependency of risk has been
found for severe retinopathy and blindness due to diabetes
(33). The reasons for this age-at-onset effect could be, for
example, genetic, endocrine, or health care related. It
could be argued that children and families who become
used to insulin treatment at an early age might adhere
better to treatment and diet than those that are diagnosed
with diabetes at an older age and especially during pu-
berty. Previous studies (17,34) have indicated that prepu-
bertal years with diabetes involve a reduced risk or a
longer time to development of diabetic nephropathy and
retinopathy. It also has long been speculated that puberty,
characterized by rapid growth, hormonal changes (espe-
cially in growth hormone and sex hormones), and wors-
ening in glycemic control, may accelerate the processes
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FIG. 1. Cumulative incidences of developing ESRD in male and female patients with type 1
diabetes onset at 0–9, 10–19, and 20–34 years. For patients with diabetes onset before 10
or 10–19 years of age, there is no signiﬁcant difference between male and female subjects
(P  0.53 and P  0.50), but with onset at 20–34 years of age there is a difference, although
borderline signiﬁcant, between male and female subjects in risk of developing ESRD (P 
0.05).
TABLE 4
Cumulative incidences of ESRD, by age at onset and sex, at different diabetes durations
Age at diagnosis
(years)
Duration of type 1 diabetes (years)
20 years (male/female) 25 years (male/female) 30 years (male/female)
0–9 0.1 (0.0–0.4)/0.2 (0.1–0.7) 1.4 (0.7–2.4)/0.7 (0.3–1.4) 2.3 (1.3–3.8)/1.9 (0.9–3.6)
10–19 1.0 (0.6–1.7)/1.3 (0.8–2.0) 3.3 (2.3–4.6)/2.4 (1.5–3.5) 5.3 (3.5–7.5)/3.2 (2.1–4.8)
20–34 1.0 (0.6–1.7)/0.7 (0.3–1.5) 6.1 (1.5–15.5)/1.1 (0.4–2.5) -
0–34 0.7 (0.5–1.0)/0.7 (0.5–1.1) 2.6 (2.0–3.3)/1.4 (1.0–2.0) 4.1 (3.1–5.3)/2.5 (1.7–3.5)
Data are incidence rate (95% CI). The cumulative incidence is estimated using the Kaplan-Meier method and given as percent.
AGE AT ONSET AND SEX IN END-STAGE RENAL DISEASE
1806 DIABETES, VOL. 59, JULY 2010 diabetes.diabetesjournals.orgleading to chronic diabetes complications (35,36). We
speculated that if puberty was a strong determinant for
development of diabetic nephropathy, then diabetes onset
after puberty would give a similar risk as prepubertal
onset. In our study, this was found in female subjects only.
In male subjects, the ESRD risk was increased also after
puberty compared with onset of diabetes at 0–9 years of
age. The group with age at onset at 10–19 years includes
both prepubertal and postpubertal cases, which could
dilute the actual effect of puberty; however, this group
includes almost all with diabetes onset during the pubertal
years.
Male sex has been reported to be a risk factor for
development of diabetic nephropathy, even though this
relationship is not as strong as in nondiabetic renal
diseases (12,14). In this study, male subjects had an
increased overall cumulative incidence of ESRD compared
with female subjects but only in patients with age at onset
of diabetes at 20 years. The higher male-to-female ratio
of ESRD found in our study is further supported by data
generated from the NDR (personal communication) show-
ing that the mean prevalence of both micro- and mac-
roalbuminuria was higher in men than in women in 2009
(15.6 vs. 11.6% and 8.4 vs. 7.2%, respectively).
The factors involved in this sex-speciﬁc difference could
possibly include lifestyle, diet, kidney and glomerular size,
differences in glomerular hemodynamics, and direct ef-
fects of sex hormones (37,38). When accounting for death
as a competing risk event, male subjects still had twice the
risk of developing ESRD, however not statistically signif-
icant, which can be explained by the higher death rates in
male subjects. Experimental evidence from animal studies
suggests that both estrogens and testosterone play a role
in the development of renal disease (39); estrogens slow
progression rate (40,41), while testosterone exacerbates it,
and the absence of testosterone attenuates the develop-
ment of renal disease (42). The pattern of cumulative
incidence by age and sex in the present study indicates
that different combinations of factors play a role in post-
pubertal development of ESRD, and further studies are
needed to conﬁrm and understand these effects.
In conclusion, the cumulative incidence of ESRD in
young patients with type 1 diabetes, with onset after 1977,
is very low in Sweden. Prepubertal age at onset of diabetes
seems to protect against, or prolong, the time to ESRD
development, and the same may be true for postpubertal
onset in female subjects (aged 20 years at onset of
diabetes). The ﬁnding of a sex difference speciﬁcally in
patients with diabetes onset after 20 years of age is of clear
interest and needs further exploration.
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